Reduction of common stock

Pursuant to company announcement no. 11, 2015, a reduction of the company’s B common stock by DKK 13,400,000 via cancellation of 6,700,000 treasury B stocks was adopted at the Annual Shareholders’ Meeting of Novozymes A/S on February 25, 2015.

Today, Novozymes has registered the final implementation of the reduction of its common stock with the Danish Business Authority. Consequently, the reduction of Novozymes’ B common stock from DKK 531,912,800 to DKK 518,512,800 is complete.
 
After the reduction, the common stock is DKK 626,000,000, divided into 313 million shares of DKK 2.
 
​Share capital overview ​Share capital, DKK ​Number of shares, DKK 2
​A-shares ​107,487,200 ​53,743,600
​B-shares ​518,512,800 ​259,256,400
​Total ​626,000,000 ​313,000,000
 
As communicated in company announcement no. 17, 2014, Novo A/S intends to reduce its relative holding of Novozymes’ B common stock so that it will continue to hold around 25.5% of the total common stock following Novozymes’ cancellation of 6,700,000 treasury B shares.
 
On March 27, 2015, following the reduction of its common stock, Novozymes' holding of treasury shares was 5.22 million B shares, equivalent to 1.67% of the reduced total share capital of DKK 626,000,000.
Contact information
Investor Relations:
 
 
Thomas Bomhoff (DK)
+45 3077 1226
Klaus Sindahl (DK)
+45 5363 0134
Martin Riise (USA)
+1 919 649 2565